Ad5:Ad48 Hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery

Molecular Therapy

Volumn 20, Issue 12, 2012, Pages 2268-2281

  Coughlan, Lynda ^a   Bradshaw, Angela C ^a   Parker, Alan L ^a   Robinson, Hollie ^a   White, Katie ^a   Custers, Jerome ^b   Goudsmit, Jaap ^b   Van Roijen, Nico ^c   Barouch, Dan H ^d   Nicklin, Stuart A ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CRUCELL HOLLAND BV   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 10; CD11B ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEXON PROTEIN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ADENOVIRUS; ADENOVIRUS 48; ADENOVIRUS 5; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME LOCALIZATION; GENE TRANSFER; GRANULOCYTE; HYPERVARIABLE REGION; IN VIVO STUDY; INFLAMMATION; INTRACELLULAR SIGNALING; KUPFFER CELL; LIVER; LIVER TOXICITY; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SEROTYPE; SPLEEN; TISSUE DISTRIBUTION; TOXICITY TESTING; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS ATTACHMENT; VIRUS DETECTION; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALIA;

EID: 84870582613     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.162     Document Type: Article

References (50)

1. Seiradake, E, Henaff, D, Wodrich, H, Billet, O, Perreau, M, Hippert, C et al. (2009). The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog 5: e1000277.
2. Carlisle, RC, Di, Y, Cerny, AM, Sonnen, AF, Sim, RB, Green, NK et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virusadenovirus receptor and complement receptor 1.Blood 113: 1909-1918.
3. Lieber, A, He, CY, Meuse, L, Schowalter, D, Kirillova, I, Winther, B et al. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
4. Alba, R, Bradshaw, AC, Mestre-Francés, N, Verdier, JM, Henaff, D and Baker, AH (2012). Coagulation factor X mediates adenovirus type 5 liver gene transfer in nonhuman primates (Microcebus murinus). Gene Ther 19: 109-113.
5. Alba, R, Bradshaw, AC, Coughlan, L, Denby, L, McDonald, RA, Waddington, SN et al. (2010). Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116: 2656-2664.
6. Nicol, CG, Graham, D, Miller, WH, White, SJ, Smith, TA, Nicklin, SA et al. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 10: 344-354.
7. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
8. Vigant, F, Descamps, D, Jullienne, B, Esselin, S, Connault, E, Opolon, P et al. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480.
9. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488.
10. Alba, R, Bradshaw, AC, Parker, AL, Bhella, D, Waddington, SN, Nicklin, SA et al. (2009). Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114: 965-971.
11. Bradshaw, AC, Parker, AL, Duffy, MR, Coughlan, L, van Rooijen, N, Kähäri, VM et al. (2010). Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog 6: e1001142.
12. Sumida, SM, Truitt, DM, Lemckert, AA, Vogels, R, Custers, JH, Addo, MM et al. (2005). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185.
13. .Bradley, RR, Maxfield, LF, Lynch, DM, Iampietro, MJ, Borducchi, EN, and Barouch, DH. (2012). Ad5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86: 1267-1272.
14. .Roberts, DM, Nanda, A, Havenga, MJ, Abbink, P, Lynch, DM, Ewald, BA et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
15. Parker, AL, Waddington, SN, Buckley, SM, Custers, J, Havenga, MJ, van Rooijen, N et al. (2009). Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol 83: 479-483.
16. .Cheng, C, Gall, JG, Nason, M, King, CR, Koup, RA, Roederer, M et al. (2010). Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 84: 630-638.
17. .Bradley, RR, Lynch, DM, Iampietro, MJ, Borducchi, EN, and Barouch, DH. (2012). Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 86: 625-629.
18. .Barouch, DH, Kik, SV, Weverling, GJ, Dilan, R, King, SL, Maxfield, LF et al. (2011). International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209.
19. .Abbink, P, Lemckert, AA, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
20. .Shayakhmetov, DM, Li, ZY, Ternovoi, V, Gaggar, A, Gharwan, H and Lieber, A (2003). The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 77: 3712-3723.
21. .Khare, R, May, SM, Vetrini, F, Weaver, EA, Palmer, D, Rosewell, A et al. (2011). Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther 19: 1254-1262.
22. .Coughlan, L, Alba, R, Parker, AL, Bradshaw, AC, McNeish, IA, Nicklin, SA et al. (2010). Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2: 2290-2355.
23. .Zhang, Z, Krimmel, J, Zhang, Z, Hu, Z and Seth, P (2011). Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum Gene Ther 22: 1137-1142.
24. .Smith, JG, Silvestry, M, Lindert, S, Lu, W, Nemerow, GR and Stewart, PL (2010). Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog 6: e1000959.
25. .Hong, SS, Habib, NA, Franqueville, L, Jensen, S and Boulanger, PA (2003). Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J Virol 77: 10366-10375.
26. .Walters, RW, Freimuth, P, Moninger, TO, Ganske, I, Zabner, J and Welsh, MJ (2002). Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 110: 789-799.
27. .Mast, TC, Kierstead, L, Gupta, SB, Nikas, AA, Kallas, EG, Novitsky, V et al. (2010). International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957.
28. .Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 78: 5368-5381.
29. .Di Paolo, NC, van Rooijen, N and Shayakhmetov, DM (2009). Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther 17: 675-684.
30. .Koizumi, N, Yamaguchi, T, Kawabata, K, Sakurai, F, Sasaki, T, Watanabe, Y et al. (2007). Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 178: 1767-1773.
31. .Di Paolo, NC, Miao, EA, Iwakura, Y, Murali-Krishna, K, Aderem, A, Flavell, RA et al. (2009). Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 31: 110-121.
32. .Bradshaw, AC, Coughlan, L, Miller, AM, Alba, R, van Rooijen, N, Nicklin, SA et al. (2012). Biodistribution and inflammatory profiles of novel penton and hexon doublemutant serotype 5 adenoviruses. J Control Release.
33. Alemany, R, Suzuki, K and Curiel, DT (2000). Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81(Pt 11): 2605-2609.
34. Ganesan, LP, Mohanty, S, Kim, J, Clark, KR, Robinson, JM and Anderson, CL (2011). Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathog 7: e1002281.
35. Lyons, M, Onion, D, Green, NK, Aslan, K, Rajaratnam, R, Bazan-Peregrino, M et al. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 14: 118-128.
36. Raper, SE, Yudkoff, M, Chirmule, N, Gao, GP, Nunes, F, Haskal, ZJ et al. (2002). A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 13: 163-175.
37. Atencio, IA, Grace, M, Bordens, R, Fritz, M, Horowitz, JA, Hutchins, B et al. (2006). Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther 13: 169-181.
38. Schiedner, G, Bloch, W, Hertel, S, Johnston, M, Molojavyi, A, Dries, V et al. (2003). A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 14: 1631-1641.
39. Muruve, DA, Barnes, MJ, Stillman, IE and Libermann, TA (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophildependent hepatic injury in vivo. Hum Gene Ther 10: 965-976.
40. Khare, R, Reddy, VS, Nemerow, GR and Barry, MA (2012). Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J Virol 86: 2293-2301.
41. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82: 11705-11713.
42. Haisma, HJ, Boesjes, M, Beerens, AM, van der Strate, BW, Curiel, DT, Plüddemann, A et al. (2009). Scavenger receptor A: a new route for adenovirus 5. Mol Pharm 6: 366-374.
43. .Coughlan, L, Vallath, S, Gros, A, Gimenez-Alejandre, M, van Rooijen, N, Thomas, GJ et al. (2012). Combined fiber modifications both to target a?ß6 and detarget CAR improve virus toxicity profiles in vivo but fail to improve anti-tumoral efficacy over Ad5. Hum Gene Ther.
44. .Shayakhmetov, DM, Gaggar, A, Ni, S, Li, ZY and Lieber, A (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79: 7478-7491.
45. .Tibbles, LA, Spurrell, JC, Bowen, GP, Liu, Q, Lam, M, Zaiss, AK et al. (2002). Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 76: 1559-1568.
46. Borgland, SL, Bowen, GP, Wong, NC, Libermann, TA and Muruve, DA (2000). Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol 74: 3941-3947.
47. Liu, Q, Zaiss, AK, Colarusso, P, Patel, K, Haljan, G, Wickham, TJ et al. (2003). The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 14: 627-643.
48. Zhu, J, Huang, X and Yang, Y (2007). Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 81: 3170-3180.
49. Coughlan, L, Vallath, S, Saha, A, Flak, M, McNeish, IA, Vassaux, G et al. (2009). In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol 83: 6416-6428.
50. Sprangers, MC, Lakhai, W, Koudstaal, W, Verhoeven, M, Koel, BF, Vogels, R et al. (2003). Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41: 5046-5052.